罗格列酮用于多囊卵巢综合征促排卵治疗的效果观察

目的　探讨罗格列酮 (rosiglitazone)对存在胰岛素抵抗的多囊卵巢综合征 (polycysticovarysyndrome ,PCOS)患者促排卵治疗的效果。 方法　选择存在胰岛素抵抗的PCOS患者 96例 ,将其随机分为A、B、C组。A组 (2 8例 )口服氯米芬、B组 (3 2例 )口服罗格列酮、C组 (3 6例 )口服罗格列酮联合氯米芬 ,3组用药时间均为 3个月经周期。比较 3组用药前后的胰岛素抵抗指数的变化和排卵情况。结果　B组和C组患者治疗后 ,应用稳态模型评估的胰岛素抵抗指数 (homeostasismodelassessmentinsulinresistance ,HOMAIR)分别由 1 2± 0 6、1 1± 0 5下降为 0 6± 0 2、0 6± 0 4,两组治疗前后比较 ,差异也有显著性 (P <0 0 5)。C组治疗后排卵率为 80 % ,明显高于A组的 59%和B组的 3 5% ,差异有显著性 (P <0 0 5)。结论　罗格列酮能有效地改善胰岛素抵抗 ,提高促排卵治疗的成功率

Effect of rosiglitazone on ovulation induction in women with polycystic ovary syndrome

OBJECTIVE: To investigate the effect of rosiglitazone on ovulation induction in women with polycystic ovary syndrome (PCOS). METHODS: Ninety-six PCOS women with insulin resistance (IR) were randomly divided into three groups. Group A (28 cases) received clomiphene citrate (CC) alone. Group B (32 cases) received rosiglitazone alone. And group C (36 cases) received CC and rosiglitazone in combination. All were treated for three menstrual cycles. Homeostasis model assessment insulin resistance (HOMA IR) and ovulation before and after treatment were compared among the 3 groups. RESULTS: After the treatment, HOMA IR in group B and C decreased from 1.2 +/- 0.6 to 0.6 +/- 0.2 and from 1.1 +/- 0.5 to 0.6 +/- 0.4, respectively (P < 0.05). Success rate of ovulation after treatment in group C (80%) was higher than that in group A (59%) and group B (35%, P < 0.05). CONCLUSION: Rosiglitazone therapy improves insulin sensitivity and ovulation induction.